TABLE 4.
post-LuTX complications and causes of death.
| TLVRS (n = 26; ✝: n = 6) | CLVRS (n = 328; ✝: n = 70*) | p = | TELVR (n = 56; ✝: n = 6) | CELVR (n = 270; ✝: n = 62*) | p = | |
|---|---|---|---|---|---|---|
| Complications | 0.754 | 0.444 | ||||
| Pleural effusion | 1 (3.8%) | 10.1% | 1 (1.8%) | 6.8% | ||
| Empyema/lung abscess | 2 (7.7%) | 1.2% | 0.014 | 3 (5.4%) | 3.1% | |
| Hemothorax | 3 (11.5%) | 6.7% | 4 (7.1%) | 6.5% | ||
| Pneumothorax/air leak | 2.7% | 2.1% | ||||
| Pneumonia | 2.3% | 1 (1.8%) | 3.0% | |||
| Phrenic nerve injury/diaph. palsy | 1.2% | 2.5% | ||||
| Wound | 1 (3.8%) | 2.7% | 5 (8.9%) | 2.5% | 0.018 | |
| Abdominal | 2 (7.7%) | 4.8% | 3 (5.4%) | 4.6% | ||
| Arrhythmia | 1 (3.8%) | 2.5% | 1 (1.8%) | 1.1% | ||
| ECMO related | 1.1% | 1 (1.8%) | 1.8% | |||
| Chest wall | 1.2% | 1.6% | ||||
| Sepsis | 0.8% | 1.8% | ||||
| PGD 3 | 3 (11.5%) | 8.3% | 2.9% | |||
| Thrombosis. embolism | 0.8% | 1 (1.8%) | 1.3% | |||
| Renal failure | 1 (3.8) | 3.6% | 1.6% | |||
| Causes of death | 0.881 | 0.031 | ||||
| Unknown | 1 (16.7%) | 26.9% | 1 (16.7%) | 14.1% | ||
| Sepsis | 1 (16.7%) | 13.0% | 25.0% | |||
| Pneumonia | 2 (33.3%) | 18.2% | 2 (33.3%) | 11.1% | ||
| MOF | 1 (16.7%) | 7.3% | 24.1% | |||
| GI bleeding/ischemia | 1 (16.7%) | 3.3% | 10.6% | |||
| Resp. insufficiency | 1 (16.7%) | 10.2% | 25.9% | |||
| Bleeding | 2.4% | 6.4% | ||||
| Graft failure | 1 (16.7%) | 1.9% | 0.044 | 1 (16.7%) | 1.5% | 0.034 |
| Kidney failure | 1.9% | 3.9% | ||||
| Malignancy | 1.9% | 2.2% | ||||
| Cardiac arrest/failure | 3.9% | 1 (16.7%) | 6.9% | |||
| CLAD | 14.5% | 1 (16.7%) | 5.0% | |||
| Acute/humoral rejection | 6.0% | 3.6% | ||||
| Pulmonary embolism | 1.9% | |||||
| Euthanasia | 1.1% | 0.3% | ||||
| ECMO-failure | 1.5% | 1 (16.7%) | ||||
| Ischemic CVA | 2.1% | 0.2% | ||||
| Myelopathy | 0.3% |
Multiple answers were allowed; complications are expressed as percentage of whole group, causes of death in relation of total deaths; TLVRS, patients with previous LVRS; CLVRS, matched controls; TELVR, patients with previous ELVR; CELVR, matched controls; TLVRS: n = 8 patients with complications (vs. n = 92*) and n = 6 patients died (vs. n = 70*); TELVR: n = 13 with complications (vs. n = 56*) and n = 6 died (vs. n = 62*); PGD, primary graft dysfunction; MOF, multi organ failure; GI, gastro-intestinal; CLAD, chronic lung allograft dysfunction; CVA, cerebrovascular accident; *control columns are calculated on weighted data; in Wilcoxon–Mann–Whitney comparison of a single factor between two groups, p values >0.05 are not reported for improved readability. Significant p values are highlited in bold italic.